Prices delayed by at least 15 minutes | Print


ECKERT+ZIEGLER INH O.N. (EUZ)

Sell: €37.22|Buy: €37.38|Change: 0.10 (-0.27%)

Open 

€37.22


Previous close 

€37.32


Trade high 

€37.64


Volume 

36,515


Year high 

€50.05


Year low 

€28.92


Dividend yield 

1.36%


Market capitalisation 

€775.16 mn


P/E ratio 

25.23


ISIN 

DE0005659700


Share price

Performance 30/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
ECKERT+ZIEGLER INH O.N.- 0.27
More...

Company profile

Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial use. It is predominantly engaged in the business of cancer therapy, industrial radiometry, and nuclear medical imaging. The company's segments are Medical, Isotope Products, and Other. The Isotope Products segment which generates key revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. The Medical segment provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. The Other segment comprises the items of the holding company. Geographically, the company generates a majority of its revenue from Europe andthe rest from North America, Asia/Pacific, and other regions.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.